Clementine Krucker

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.

FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.

Journal: The Journal of clinical investigation
Published: March 14, 2025

Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.

Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 06, 2024

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.

Journal: The Journal of urology
Published: December 28, 2023

Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.

Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: March 08, 2023

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Journal: Cancers
Published: February 14, 2023

A new tumorgraft panel to accelerate precision medicine in prostate cancer.

A new tumorgraft panel to accelerate precision medicine in prostate cancer.

Journal: Frontiers in oncology
Published: December 22, 2022

Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.

Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.

Journal: European urology
Published: December 13, 2022

Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.

Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.

Journal: Oncogene
Published: October 18, 2022

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

Journal: Frontiers in oncology
Published: April 28, 2022

FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.

FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.

Journal: European urology
Published: November 03, 2021

Triple extraction method enables high quality mass spectrometry-based proteomics and phospho-proteomics for eventual multi-omics integration studies.

Triple extraction method enables high quality mass spectrometry-based proteomics and phospho-proteomics for eventual multi-omics integration studies.

Journal: Proteomics
Published: November 26, 2020

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Journal: Oncoimmunology
Published: October 24, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026